Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ALT News 25 November 2025 - 31 January 2026

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune, Inc. (NASDAQ: ALT) is back in the biotech spotlight on December 17, 2025—less because the company suddenly became “safe,” and more because it’s heading into the kind of binary stretch that turns small-cap biotech charts into roller coasters: a high-stakes clinical update is expected before year-end, leadership is changing hands, and Wall Street price targets remain dramatically spread out. Shares were indicated around $5.03 early Wednesday, after closing at roughly the same level on Tuesday (Dec. 16). MarketBeat Altimmune stock price action: why traders keep circling ALT ALT has been showing the classic behavior of a catalyst-driven biotech: sharp
17 December 2025
·
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets, and impending data readouts are all influencing sentiment. Below is a detailed, publication-ready look at today’s ALT stock action , the latest company and clinical news , Wall Street forecasts , and the key catalysts and risks that matter most
12 December 2025
··
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune, Inc. (NASDAQ: ALT) has become a tightly wound biotech story heading into year‑end 2025. The small‑cap developer of liver and metabolic drugs is changing its CEO just weeks before a pivotal 48‑week readout in its lead MASH trial, while Wall Street models still point to triple‑digit upside from today’s share price. As of mid‑day on December 9, 2025, Altimmune stock trades around $5.61 per share, implying a market capitalization of roughly $550 million. Stock Titan That price sits well above its autumn lows but far below analyst targets that cluster in the mid‑teens to high teens. Below is a
9 December 2025
·
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat to slightly higher versus Monday’s close. Intraday ranges have been tight so far, with trading largely clustered between about $4.8 and $5.2 per share. INDmoney On Monday, November 24, ALT: According to short‑term technical data, ALT has risen in 6 of the last 10 trading days and is up almost 20% over the past two weeks, as traders reposition ahead
25 November 2025
··

Stock Market Today

Quantum computing stocks bounce hard: IonQ, Rigetti, D‑Wave rally as traders reset for a data-heavy week

Quantum computing stocks bounce hard: IonQ, Rigetti, D‑Wave rally as traders reset for a data-heavy week

7 February 2026
IonQ, Rigetti, D‑Wave, and Quantum Computing Inc shares surged 15–21 percent Friday, erasing losses from the previous session. The rebound followed a Wall Street rally that sent the Dow above 50,000 for the first time. IonQ remains under scrutiny after a short-seller report questioned its Pentagon contract revenue. Investors await delayed U.S. jobs and inflation data next week.
Defense and space stocks rally, but Trump’s buyback-dividend squeeze is the next test

Defense and space stocks rally, but Trump’s buyback-dividend squeeze is the next test

7 February 2026
U.S. space and defense stocks rose Friday, with sector ETFs gaining up to 4.8% and Lockheed Martin up 2.4%. Investors are awaiting a Pentagon list that could restrict buybacks and dividends at underperforming contractors under a Trump executive order. Companies named would have 15 days to submit remediation plans. Lockheed’s board approved a $3.45 per share dividend for Q1 2026.
Ucore Rare Metals stock price jumps as ‘Project Vault’ keeps rare earths on traders’ screens

Ucore Rare Metals stock price jumps as ‘Project Vault’ keeps rare earths on traders’ screens

7 February 2026
Ucore Rare Metals shares jumped 14.7% to C$7.97 on Toronto’s TSX Venture Exchange Friday, rebounding after a steep drop as investors responded to U.S. critical-minerals policy moves. The U.S. Export-Import Bank described Project Vault as a $10 billion public-private stockpiling plan. Neodymium prices climbed 1.27% to 997,500 yuan a tonne on Feb. 6. Investors await details on Project Vault’s purchasing plans next week.
Semiconductor stocks surge as AI capex stays high; Nvidia and AMD lead into next week

Semiconductor stocks surge as AI capex stays high; Nvidia and AMD lead into next week

7 February 2026
The Philadelphia Semiconductor Index jumped 5.7% to 8,048.6 on Friday, with Nvidia up 7.87% and AMD rising 8.28%. The surge followed new forecasts showing global chip sales could hit $1 trillion in 2026. Amazon expects a 50% increase in capital spending this year, fueling demand for chips. The Dow Jones crossed 50,000, helped by gains in chipmakers.
Go toTop